For decades, the standard approach to bone loss has been surgical intervention—grafts, membranes, growth factors. These methods can work, but they're invasive, unpredictable, and fundamentally misaligned with how bone actually regenerates.
Bone is not a static tissue. It's a living, dynamic structure that constantly remodels itself in response to mechanical stress. This isn't a new discovery—Julius Wolff described it in 1892. What's remarkable is that 130 years later, we still haven't built therapies around this principle.
The Physics of Bone
When you walk, chew, or move, mechanical forces travel through your skeleton. These forces generate tiny electrical signals through a phenomenon called piezoelectricity. Your bones convert pressure into voltage—and that voltage tells your body where to build new bone.
This is why astronauts lose bone mass in space. Without gravity, there's no mechanical loading. Without loading, there's no piezoelectric signal. Without the signal, osteoblasts don't know where to work.
The Gap We Saw
When my co-founder and I looked at the periodontal market, we saw a $30 billion problem with no good solutions. Over 40% of American adults have periodontal disease. The bone loss it causes is considered irreversible unless you undergo surgery—and even then, outcomes are inconsistent.
We asked: what if we could deliver a piezoelectric signal directly to the defect site? What if we could tell the body exactly where to regenerate bone, using its own mechanical energy as the power source?
Building the Platform
That question became Oral BioLife. Our piezoelectric regenerative platform doesn't add external drugs or biologics. It converts the natural micromotion of daily function—chewing, speaking, breathing—into localized bioelectrical signals that activate physiological bone formation.
The scaffold is biodegradable. The mechanism is endogenous. The regulatory pathway is clean.
What's Next
We've demonstrated 100% bone regeneration response in pre-clinical canine models. Our lead program, Ambrilux™ Dental Gel, is advancing toward first-in-human studies in 2026. And we're already exploring applications beyond periodontal disease—peri-implantitis, craniofacial defects, orthopedic indications.
Bone loss has been treated as irreversible for too long. We're building the platform to change that.